Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer.

Abstract

2517 (2015). 12 Patel MR, Bauer TM, Liu SV et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33(Suppl.), Abstract 2596 (2015). 13 Burris HA, Brose MS, Shaw AT et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J. Clin. Oncol. 33(Suppl.), Abstract TPS2624 (2015). 14 TRK inhibitor shows early promise. Cancer Discov. doi:10.1158/2159-8290.CDNB2015-165 (2015) (Epub ahead of print).